MRPL18

Across TCGA pan-cancer cohorts, MRPL18 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRPL18 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MRPL18 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MRPL18 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, GBM, and LUAD are the cancer types where MRPL18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	1.000	0.705	.005	15	view →
GBM	OS	Median	All	0.616	0.430	.009	6	view →
LUAD	DFS	Tertile	II,III,IV	0.947	0.688	.032	3	view →
CCRCC	DFS	Quartile	II,III,IV	0.310	0.659	.041	2	view →
PDAC	DFS	Tertile	All	0.847	0.631	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRPL18–LSCC (OS)

Open the LSCC breakdown →